AzTrials
AzTrials

Lung CancerNCT02440139

Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC

A study testing ClearRead CT Insight in people with Lung Cancer, run by Virginia Polytechnic Institute and State University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

STUDY DESIGN: This is a retrospective, multi-reader, multi-case, (MRMC) randomized reader study. OBJECTIVE: Primary: The primary objective of this clinical study is to prove that a user aided with ClearRead CT InSight (CRCTI) is superior to the unaided reader for detecting actionable lung nodules. Read more about this study

Who is it for?
Ages 55 to 77 years
Conditions the study is for
Lung Cancer
What is being tested?
ClearRead CT Insight
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
12 participants
Where
1 siteUnited States
Study dates
Apr 2015to Mar 2018
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 55 to 77 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • A thoracic CT case that is associated or with a feature of the following:
  • Asymptomatic patients age 55 - 77 with history of smoking
  • Primary Lung Cancer
  • Biopsy Proven (LuRADS 5) with radiology report
  • Screen detected event plus 1 prior CT. 2 year of prior CTs is preferred, if available.
  • <= 3mm slice spacing, no gaps
Show all 10Show fewer
  • Use standard reconstruction kernels
  • Maximum of 5 nodules per image
  • Nodules must be 5-20mm in size
  • With or without contrast

Who cannot join

  • Thoracic CT cases that meet the following exclusion criteria will not be collected for use during clinical testing.
  • No Acute pneumothorax
  • Both lungs must be fully visible within the field of view
  • Apices cannot be cropped
  • No excessive motion artifacts
  • Symptomatic patients with co-morbidities

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Arlington Innovation Center: Health Resaerch

    Arlington, Virginia, 22203

Other trials in United States

About this study

Official title: Computer-Aided System for the Improvement of Nodule Detection and Characterization in Thoracic CT Based on a Novel Vessel Suppressed CT Volume

STUDY DESIGN:

This is a retrospective, multi-reader, multi-case, (MRMC) randomized reader study.

Read more

OBJECTIVE:

Primary: The primary objective of this clinical study is to prove that a user aided with ClearRead CT InSight (CRCTI) is superior to the unaided reader for detecting actionable lung nodules.

Secondary: The secondary objective of this clinical study is to prove that the reader's reading time is not significantly increased when aided with CRCTI.

NUMBER OF SUBJECTS:

Retrospective CT studies from approximately 300 patients will be included in the study. Approximately 100 true positive cases and 200 normal cases.

NUMBER OF READERS:

A reader study with at least ten (10) participating radiologists (US Board Certified) will be conducted.

PRIMARY ENDPOINTS:

Scores given by the radiologists with and without ClearRead CT Insight will be recorded and compared to the true status of the study-cases. The frequency of the scores for each method (Unaided, Aided) will be tabulated and LROC curves constructed along with sensitivity, specificity, PPV, NPV and clinical actions. Additionally, machine nodule detection rate and false positives per patient on normal cases will be measured.

PATIENT POPULATION :

The study will target approximately one hundred (100) patients whose CT nodules were shown to be cancer and two hundred (200) normal patients. The patient population will be consistent with the national lung cancer screening protocols.

Read the detailed description

A reader study with at least ten (10) participating radiologists will be conducted. A localized receiver operating characteristic curve will be used to evaluate radiologists' diagnostic performance (in terms of the trade-off between the sensitivity and specificity when the decision criteria changes) in the detection of lung nodules on lung CTs with and without the usage of the ClearRead CT Insight (CRCTI) system. The time needed for the review and interpretation of each case will also be recorded.

An initial (baseline) interpretation will be made by each of the radiologists based on the Lung CT in its original form. At a minimum of one month later, each radiologists will again interpret the same images viewing the pair of CRCTI CT series: Two sets of CT images (standard with CADe marks and processed with vessel suppression will be presented on either one large monitor or two adjacent monitors.

During the baseline reading the radiologist will mark the location of the actionable nodules and assign a score. The radiologist will also indicate the recommended method of follow-up (Contrast CT, PET-CT, CT Follow-up, Biopsy).

During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with computer-aided detection (CADe) marks placed and the vessel suppressed same slice with the vessel suppressed view (right image). The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).

Based on the levels of suspicion for each nodule and the associated likelihood ratings, LROC curves will be constructed for both the baseline and the concurrent reads and the significance of any difference will be calculated. The recommendations for further action (CT Follow-up, Contrast CT, PET-CT, or Biopsy) will be used to calculate sensitivity and specificity, PPV and NPV.

Number and types of cases:

Retrospective lung CT image series from approximately 300 patients will be included in the study. Approximately one hundred (100) of the patients will have pathology confirmed cancers and approximately two hundred (200) of the patients will be CTs associated with normal patients. Also included as nodule images are those where the actionable nodule was not acted on at that time, but was detected and acted on based on a subsequent CT. These are the prior images where the nodule can be identified and its location is the same as on the "current" image confirmed by the radiologist expert panel (using a majority of three as the decision criterion).

The selected sample, randomly selected from a larger pool of CT cases will be enriched in the following way:

  1. Lung nodules (cancers in this study) will be tumor size T1a (20 mm or less). The proportion of nodules 20 mm or less may be increased since this is where the investigators expect the major impact of this software to be.
  2. Non-Solid (ground glass) nodules will be added to the sample (based on availability) to determine the performance of the system on non-solid nodules. For this group, to have sufficient cases, the investigators may have to include benign (non-malignant) non-solid nodules.
  3. In this project, the investigators will perform a Machine Test of the ClearRead CT Insight algorithm followed by a reader performance evaluation study. Riverain will provide a system configured with the operating point set to be used for the reader studies and a configuration for an "open" system to be used for machine testing and FROC generation.

Arm 1: a baseline read (no secondary content) and Arm 2: concurrent, CAD augmented read.

  1. st Arm: Do baseline (measure time, readers score regions according to action and suspiciousness) - mark all locations of concern
  2. nd Arm: Concurrent read (measure time, readers score regions according to action and suspiciousness) - mark all locations of concern

The primary study hypothesis is that the adjunctive use of ClearRead CT Insight is superior to use of standard lung CT images alone, as measured by the area under the LROC curve.

STATISTICAL ANALYSES Accuracy

To evaluate the hypothesis of superiority in terms of improvement in accuracy for ClearRead CT Insight vs. unaided, a mixed effects model (DBM) will be implemented (similar to the model outlined in Dorfman, Berbaum and Metz, 1997), where variance components will be included to account for reader, case, reader by case, reader by modality, case by modality and reader by case by modality. However, it is anticipated that the three-way interaction will be inestimable and will subsequently be dropped from the statistical model. Specifically, the hypothesis to test for superiority of ClearRead CT Insight vs. unaided is:

H0: AUCunaided - AUCClearRead CT Insight ≥ 0.0 vs. HA: AUCunaided - AUCClearRead CT Insight < 0

The AUC of the LROC is the primary endpoint to evaluate accuracy and the test of interest will be a two-sided 95% confidence interval on the effect of modality (i.e. ClearRead CT Insight minus unaided). Significance will be concluded if the upper bound of the two-sided 95% confidence interval does not include zero. If the null hypothesis (H0) is rejected, the alternative hypothesis (HA) is accepted and the superiority of using the ClearRead CT Insight system will be established.

Time

The second co-primary objective is to evaluate reduction in time spent per image for ClearRead CT Insight vs. unaided. Specifically, the hypothesis to test for superiority of ClearRead CT Insight vs. unaided is:

H0= Tunaided - TClearRead CT Insight ≤ 0 vs. HA= Tunaided - TClearRead CT Insight > 0

To evaluate the hypothesis of non-inferiority in terms of improved read time for ClearRead CT Insight vs. unaided, a mixed effects model will be implemented (similar to the model outlined in Dorfman, Berbaum and Metz, 1992), where variance components will be included to account for reader, case, reader by case, reader by modality, case by modality and reader by case by modality. However, it is anticipated that the three-way interaction will be inestimable and will subsequently be dropped from the statistical model.

The read times will be tested using a two-sided 95% confidence interval on the effect of modality (i.e. ClearRead minus unaided). Significance will be concluded if the upper bound of the two-sided 95% confidence interval does not include zero.

With either analysis, the use of the mixed model could be modified to employ a bootstrap sampling approach if the model assumptions of the DBM method have been violated. The upper 95 % confidence limit for the difference in the areas under the curves would be calculated using 10,000 bootstraps in the MultiReader MultiCase (MRMC) ROC method.

POWER AND SAMPLE SIZE

The power to detect differences in the AUC of the LROC curve for the proposed statistical analysis using the current design baseline, i.e. 300 cases, each corresponding image read by 10 readers, was assessed through a simulation study. Specifically, the model outlined above was used to simulate 500 datasets across a range of effect sizes, where power was defined as the proportion of datasets that yielded a significant p-value for testing the fixed effect of modality. The method of Dorfman, Berbaum and Metz, 1992 (DBM) was implemented utilizing statistical mixed model theory with jackknife estimates.

These simulations required assumptions regarding the magnitude of the variance components associated with the different random effects. As a pilot study to obtain estimates of variance components was not conducted, variance component estimates from Riverain study SoftView 510(k) (Record # BSSI-PR-09-00006) that uses a similar technology as the proposed ClearRead CT Insight device were used in all power simulations. Please note that the variance components were scaled by the total variance to represent the proportion of total variance explained by each component. All power estimates are dependent upon the appropriateness of the assumed variance components.

Conditions
Lung Cancer
Being tested
ClearRead CT Insight
Medical subject headings
Lung Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ClearRead CT InsightDevice

    During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).

Study groups in NCT02440139
Study groupRoleWhat they receive
Arm 1No interventionParticipating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
Arm 2Active comparatorParticipating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.
Receives: Device: ClearRead CT Insight

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules

    The detection rates in accuracy, sensitivity, and specificity on clinically actionable lung nodules were computed and compared for Aim 1 (baseline) and Arm 2 (study participants were aided with ClearRead CT software) studies.

    Measured: 4 months

  2. Comparing LROC Curve in the Detection of Clinically Actionable Lung Nodules Among Normal

    The areas under location-specific Receiver Operating Characteristic (LROC) curves were computed and compared for Aim 1 (baseline) and Aim 2 (study participants were aided with ClearRead CT software).

    Measured: 4 months

Secondary outcomes (1)
  1. Average Reading Time Per Case

    The average reading times per reader per case were computed and comapred in both Aim 1 and Arm 2 (study participants were aided with ClearRead CT software) studies.

    Measured: 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 May 2015 (estimated)
  2. Study startApr 2015
  3. Primary completionSep 2017
  4. Study completionMar 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
12 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02440139
Sponsor's protocol ID
458420
Status last verified
Nov 2021
First submitted
15 Apr 2015
Last updated
4 Nov 2021
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Beyer F, Zierott L, Fallenberg EM, Juergens KU, Stoeckel J, Heindel W, Wormanns D. Comparison of sensitivity and reading time for the use of computer-aided detection (CAD) of pulmonary nodules at MDCT as concurrent or second reader. Eur Radiol. 2007 Nov;17(11):2941-7. doi: 10.1007/s00330-007-0667-1. Epub 2007 May 22.

    PubMed 17929026
  • Dorfman DD, Berbaum KS, Metz CE. Receiver operating characteristic rating analysis. Generalization to the population of readers and patients with the jackknife method. Invest Radiol. 1992 Sep;27(9):723-31. No abstract available.

    PubMed 1399456
  • Foti G, Faccioli N, D'Onofrio M, Contro A, Milazzo T, Pozzi Mucelli R. Evaluation of a method of computer-aided detection (CAD) of pulmonary nodules with computed tomography. Radiol Med. 2010 Sep;115(6):950-61. doi: 10.1007/s11547-010-0556-6. Epub 2010 Jun 23. English, Italian.

    PubMed 20574707
  • Matsumoto S, Ohno Y, Aoki T, Yamagata H, Nogami M, Matsumoto K, Yamashita Y, Sugimura K. Computer-aided detection of lung nodules on multidetector CT in concurrent-reader and second-reader modes: a comparative study. Eur J Radiol. 2013 Aug;82(8):1332-7. doi: 10.1016/j.ejrad.2013.02.005. Epub 2013 Mar 6.

    PubMed 23480965
  • Obuchowski NA. New methodological tools for multiple-reader ROC studies. Radiology. 2007 Apr;243(1):10-2. doi: 10.1148/radiol.2432060387. No abstract available.

    PubMed 17392244
  • Obuchowski NA, McClish DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Stat Med. 1997 Jul 15;16(13):1529-42. doi: 10.1002/(sici)1097-0258(19970715)16:133.0.co;2-h.

    PubMed 9249923

Questions about this trial

What is this clinical trial studying?

A study testing ClearRead CT Insight in people with Lung Cancer, run by Virginia Polytechnic Institute and State University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 4 Oct 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules (time frame: 4 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02440139, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in